Pliant Therapeutics, Inc. PLRX
1.08
(0.06)
(5.26%)
as of 25 Sep
- Market cap
- $70.6M
- P/E
- 0.0×
Follow PLRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | 6.66 | 1.39 | — | — |
P/S ratio |
— | — | 209.79 | 82.43 | 63.91 | 11.60 | 0.00 | — | — |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
P/Operating CF |
— | — | (42.01) | (25.55) | (24.36) | (29.42) | (3.17) | — | — |
P/B ratio |
— | — | 2.23 | 2.55 | 2.43 | 1.71 | 0.00 | — | — |
Price to Tangible BV |
— | — | 2.23 | 2.55 | 2.43 | 1.71 | 0.00 | — | — |
EV/Sales |
— | — | 113.47 | 49.26 | 38.12 | 4.98 | 0.00 | — | — |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
EV/Operating CF |
— | — | (4.90) | (5.04) | (3.83) | (5.58) | 21.63 | — | — |
EV/FCF |
— | — | (4.86) | (4.95) | (3.73) | (5.36) | 17.69 | — | — |
Quick Ratio |
11.67 | 10.71 | 17.33 | 13.94 | 12.04 | 24.68 | 13.48 | 12.09 | — |
Current Ratio |
12.00 | 10.91 | 17.72 | 14.23 | 12.44 | 25.07 | 13.69 | 12.14 | — |
Net Debt/EBITDA |
1.27 | 1.45 | 2.59 | 2.53 | 2.06 | 6.86 | 870.96 | 2.01 | — |
Debt/Assets |
0.00% | 7.61% | 1.96% | 2.83% | 2.41% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.10 | 0.02 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.20 | 0.61 | 0.00 | — |
Operating CF/Net income |
0.86 | 0.74 | 0.72 | 0.77 | 0.78 | 0.90 | 0.40 | 0.81 | — |
Capex/Depreciation |
(0.04) | (0.83) | 0.29 | (103.53) | (0.70) | (1.17) | (0.87) | (3.49) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| (61.55%) | (54.09%) | (41.00%) | (48.13%) | (40.35%) | (40.17%) | 9.28% | 47.58% | — | |
| (48.01%) | (46.27%) | (37.40%) | (43.13%) | (37.64%) | (20.04%) | (7.39%) | (105.67%) | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (1,609.28%) | (422.05%) | (10.68%) | 0.00% | — |
Return on Tangible Assets |
(81.60%) | (62.86%) | (33.57%) | (38.43%) | (49.32%) | (14.65%) | (6.36%) | (57.71%) | — |
Average Days of Receivables |
— | — | 0.00 | 77.86 | 100.31 | 81.72 | 47.25 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 8,088.42% | 1,000.89% | 1,024.15% | 158.29% | 83.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 3,666.33% | 412.48% | 363.95% | 41.30% | 19.16% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2,815.38% | 233.33% | 137.84% | 9.31% | 3.21% | 0.00% | — |
Graham Net Nets |
— | — | 0.44 | 0.38 | 0.39 | 0.57 | 4.10 | — | — |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | 31.90 | 20.27 | — | — |
Earnings Yield |
— | — | (15.37%) | (15.63%) | (20.07%) | 15.01% | 72.15% | — | — |
Free Cash Flow Yield |
— | — | (11.12%) | (12.07%) | (15.99%) | (8.00%) | (14.13%) | — | — |
Revenue per Share |
0.00 | 0.00 | 0.03 | 0.23 | 0.21 | 1.96 | 35.14 | 0.00 | — |
Operating CF per Share |
(2.09) | (2.57) | (1.98) | (2.25) | (2.10) | (1.75) | (1.69) | (24.31) | — |
Capex per Share |
0.00 | (0.06) | (0.02) | (0.04) | (0.05) | (0.07) | (0.59) | (1.99) | — |
Free Cash Flow per Share |
(2.09) | (2.63) | (2.00) | (2.29) | (2.16) | (1.82) | (2.29) | (26.30) | — |
Cash per Share |
3.11 | 5.88 | 8.42 | 7.88 | 5.60 | 12.97 | 63.31 | 52.29 | — |
Shareholders Equity per Share |
2.95 | 5.02 | 8.07 | 7.46 | 5.55 | 13.26 | 67.75 | 52.02 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
2.95 | 5.02 | 8.07 | 7.46 | 5.55 | 13.26 | 67.75 | 52.02 | — |
Free Cash Flow |
(128.55) | (159.35) | (117.28) | (96.39) | (77.40) | (38.80) | (3.71) | (30.65) | — |
Working Capital |
180.08 | 329.05 | 476.98 | 316.40 | 192.61 | 279.16 | 103.73 | 56.65 | — |
Capital Expenditures |
(0.22) | (3.85) | (0.92) | (1.76) | (1.95) | (1.53) | (0.96) | (2.32) | — |
Net Current Asset Value |
152.43 | 269.40 | 466.92 | 303.04 | 187.29 | 278.29 | 102.82 | 55.84 | — |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Capex to Sales |
0.00 | 0.00 | 0.58 | 0.18 | 0.26 | 0.04 | 0.02 | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | (10,211.14%) | (1,273.32%) | (1,284.51%) | (99.32%) | (12.02%) | 0.00% | — |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.68 | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
1.92 | 0.84 | (0.88) | 0.00 | 0.61 | 0.30 | 0.27 | 0.16 | — |
Cash ROIC |
(35.28%) | (23.34%) | (12.26%) | (15.14%) | (19.77%) | (7.43%) | (3.21%) | (26.80%) | — |
Accounts Receivable Turnover |
— | — | 0.00 | 4.67 | 1.32 | 4.99 | 14.47 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | — |
Average Receivables |
— | — | — | 2.07 | 5.72 | 8.37 | 3.94 | 3.94 | — |
Average Payables |
3.22 | 5.25 | 3.06 | 2.28 | 2.50 | 1.64 | 1.91 | 1.91 | — |
Average Assets |
311.09 | 454.55 | 431.38 | 285.91 | 258.37 | 207.30 | 92.80 | 33.26 | — |
Average Common Equity |
242.64 | 388.83 | 393.46 | 256.20 | 241.06 | 103.38 | (73.88) | (73.88) | — |
Columns are period end dates